Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

NCT07551037 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Personalized Active Immunotherapy
Maintenance Therapy

Interventions

BIOLOGICAL: Active Immunotherapy
OTHER: after 6 courses of routine consolidation chemotherapy
OTHER: during 6 courses of routine consolidation chemotherapy

Sponsor

Fujian Medical University Union Hospital